VENTURE CAPITAL FUND
Unicircles Rank: 1
Venture Capital Fund in New York City
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Community Valuation
Undervalued
(1 vote undervalued, 0 votes overvalued)
Investment preferences:
Early-stage Startup Capital (VC) and Mid-stage Expansion Capital (VC, PE)
Investment Sector:
Analytics / Algorithms / AI, Biotech / Health Care, Clean / Green Tech, and Consumer E-Commerce
Common Investment amount:
25M+ (USD)
Assets under Mgmt:
1B - 5B (USD)
Board / CXO / Strategy / Partner
Environmental Engineering
OPPORTUNITIES AT Aisling Capital